Clinical Significance of HRNR Expression in Patients With Stage II/III Gastric Cancer After Curative Gastrectomy.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2024-10-01 DOI:10.21873/anticanres.17287

Takashi Oshima, Itaru Hashimoto, Yukihiko Hiroshima, Yayoi Kimura, Mie Tanabe, Yuta Nakayama, Shinsuke Nagasawa, Kyohei Kanematsu, Toru Aoyama, Takanobu Yamada, Takashi Ogata, Yohei Miyagi

{"title":"Clinical Significance of HRNR Expression in Patients With Stage II/III Gastric Cancer After Curative Gastrectomy.","authors":"Takashi Oshima, Itaru Hashimoto, Yukihiko Hiroshima, Yayoi Kimura, Mie Tanabe, Yuta Nakayama, Shinsuke Nagasawa, Kyohei Kanematsu, Toru Aoyama, Takanobu Yamada, Takashi Ogata, Yohei Miyagi","doi":"10.21873/anticanres.17287","DOIUrl":null,"url":null,"abstract":"Background/aim: The function of the S-100 protein family member hornerin (HRNR) in gastric cancer (GC) tissues is largely unknown. We researched the clinical significance of HRNR expression in GC tissues of patients with pathological (p)Stage II/III GC after curative resection.Patients and methods: We included patients with pStage II/III GC who underwent curative gastrectomy (n=253). Expression levels of HRNR in GC tissue and in the adjacent normal mucosa were determined using quantitative real-time polymerase chain reaction. Clinicopathological features and overall survival (OS) were compared in patients with different HRNR expression levels in GC tissue.Results: HRNR expression levels were significantly higher in GC tissues than in the adjacent normal mucosa. HRNR expression level in GC tissue showed sex differences. The 5-year OS rate in the high-HRNR expression group was significantly worse than that in the low-expression group (5-year survival 53.6% vs. 74.9%; p=0.004). Furthermore, on multivariate analysis, high-HRNR expression was an independent predictor of poor OS (hazard ratio=1.534; 95% confidence interval=1.130-2.618; p=0.011).Conclusion: In patients with pStage II/III GC after curative gastrectomy, HRNR expression in GC tissue may be a useful prognostic marker.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4579-4584"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The function of the S-100 protein family member hornerin (HRNR) in gastric cancer (GC) tissues is largely unknown. We researched the clinical significance of HRNR expression in GC tissues of patients with pathological (p)Stage II/III GC after curative resection.

Patients and methods: We included patients with pStage II/III GC who underwent curative gastrectomy (n=253). Expression levels of HRNR in GC tissue and in the adjacent normal mucosa were determined using quantitative real-time polymerase chain reaction. Clinicopathological features and overall survival (OS) were compared in patients with different HRNR expression levels in GC tissue.

Results: HRNR expression levels were significantly higher in GC tissues than in the adjacent normal mucosa. HRNR expression level in GC tissue showed sex differences. The 5-year OS rate in the high-HRNR expression group was significantly worse than that in the low-expression group (5-year survival 53.6% vs. 74.9%; p=0.004). Furthermore, on multivariate analysis, high-HRNR expression was an independent predictor of poor OS (hazard ratio=1.534; 95% confidence interval=1.130-2.618; p=0.011).

Conclusion: In patients with pStage II/III GC after curative gastrectomy, HRNR expression in GC tissue may be a useful prognostic marker.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胃切除术后 II/III 期胃癌患者 HRNR 表达的临床意义

背景/目的：S-100蛋白家族成员角蛋白（HRNR）在胃癌（GC）组织中的功能尚不清楚。我们研究了HRNR在接受根治性切除术的病理（p）II/III期GC患者的GC组织中表达的临床意义：我们纳入了接受根治性胃切除术的p期II/III GC患者（n=253）。采用定量实时聚合酶链反应法测定GC组织和邻近正常黏膜中HRNR的表达水平。比较了GC组织中不同HRNR表达水平患者的临床病理特征和总生存率（OS）：结果：HRNR在GC组织中的表达水平明显高于邻近的正常粘膜。GC组织中的HRNR表达水平存在性别差异。高HRNR表达组的5年OS率明显低于低表达组（5年生存率为53.6%对74.9%；P=0.004）。此外，在多变量分析中，高HRNR表达是不良OS的独立预测因子（危险比=1.534；95%置信区间=1.130-2.618；P=0.011）：结论：对于接受胃切除术的P期II/III GC患者，GC组织中HRNR的表达可能是一个有用的预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.